ROSETTA Lung-107
ROSETTA Lung-107 examines whether pumitamig with chemotherapy can improve outcomes in NSCLC, with discussion focused on docetaxel after chemoimmunotherapy. In the sources reviewed for this edition, favorable clinical reactions coexist with an unresolved added-benefit question. A medical oncologist expresses safety reassurance and relayed investigator remarks welcome activity; X-thread discussions scrutinize comparative benefit. How subgroup findings should guide treatment selection, and how alternative docetaxel combinations compare, remain open.
- NCT06841055 ↗
- v1.0.0 · edition 1
- updated Oct 28, 2026
- Focused
4 findings, and what sits behind each
01. An encouraging signal leaves the added-benefit question unanswered
5 statements · 2 passages · 2 sources · 2 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Design and conduct, Secondary endpoints, The comparison, Primary endpoint: Part 1 and Part 2 - Objective response rate, Population and setting.
02. Reassurance about safety coexists with high-grade toxicity and differing bleeding summaries
5 statements · 3 passages · 3 sources · 3 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest, Safety and tolerability, Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs), Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events, Population and setting.
03. Activity across subgroups supports further study, not a selection rule or proven mechanism
4 statements · 3 passages · 3 sources · 3 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Part 1 and Part 2 - Objective response rate, Population and setting, Secondary endpoints.
04. Strategy-level enthusiasm does not rank alternative docetaxel combinations
2 statements · 2 passages · 2 sources · 2 named voices
Counterview: none recorded · Limitations recorded: 2.
Draws on: Population and setting, Primary endpoint: Part 1 and Part 2 - Objective response rate, Secondary endpoints, The comparison, Design and conduct.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 4
An encouraging signal leaves the added-benefit question unanswered
- statements
- 5
- passages
- 2
- sources
- 2
- named voices
- 2
What the statements areViews 1Questions and uncertainty 1Clinical experience 0Comparisons 1Restated results and context 2How passages are usedSupporting a statement 5Giving context 0Recorded with the finding- Counterview: none recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 2 posts and articles
Draws on: Design and conduct, Secondary endpoints, The comparison, Primary endpoint: Part 1 and Part 2 - Objective response rate, Population and setting.
In the full report: the interpretation in full, all 5 statements cited to source and date, and the 2 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full ROSETTA Lung-107 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
Would a randomized comparison show that adding pumitamig improves outcomes over contemporary second-line treatment?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 14HCP commentary sources screened
- 5sources cited by verified HCP statements
- 2found in screened sources
- 2matched to verified clinician profiles
- 2voices cited in the report
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 16verified statements, each linked to its source
- 2of them from speakers with a confirmed clinical role
- 4findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 16 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 16 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 5 | Counts free |
| Speaker attribution for cited voices | 2 | Paid |
Trial aspects
12 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs) | 2 | 2 |
| Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest | 5 | 3 |
| Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events | 1 | 1 |
| Primary endpoint: Part 1 and Part 2 - Objective response rate | 7 | 4 |
| Secondary endpoints | 7 | 4 |
| Population and setting | 8 | 5 |
| The comparison | 4 | 3 |
| Safety and tolerability | 5 | 3 |
| Design and conduct | 5 | 3 |
| PD-L1 and histology: breadth of activity versus differential benefit | 4 | 3 |
| Potential immune re-engagement after chemoimmunotherapy | 1 | 1 |
| Alternative immune–angiogenic combinations | 1 | 1 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 13 | 5 | |
| Bluesky threads | 1 | 0 |
max 13 / quarter
- Screened window
- Sep 26, 2026 → Oct 25, 2026
- Cited window
- Oct 25, 2026 → Oct 25, 2026
- Retrieved
- Oct 28, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
- Registry
- NCT06841055
- Study IDs
- BNT327-07 · 2024-518279-80-00
- Sponsor
- BioNTech SE
- Collaborators
- BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- Design
- Phase 2 · Interventional, non randomized, sequential
- Status
- Recruiting
- Enrollment
- 60 estimated
- Start
- 2025-03-03 actual
- Primary completion
- 2028-10 estimated
- Primary endpoint
- Part 1 - Occurrence of dose limiting toxicities (DLTs)
- Interventions
- 2 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative survey of HCPs. Presentation summaries, relayed statements and account commentary should not be counted as independent clinician endorsements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No results publication for NCT06841055 was found, no protocol was listed on ClinicalTrials.gov, and no exact pumitamig regulatory label was identified. The report describes commentary, not a complete assessment of the trial or prescribing information.
- The safety summaries differ on bleeding severity, reporting grade 1 versus grades 1 or 2; the available statements do not explain the difference.
- Historical and cross-study comparisons, descriptive subgroup results and a relayed mechanistic hypothesis do not establish comparative efficacy, comparative safety or a treatment-selection rule.
How reports are built and checked: Methods.
Editions and corrections
freeShow all 2 corrections
None of these corrections changed a finding.
- Oct 28, 2026The trial is named ROSETTA Lung-107, as its sources and the report name it (was BNT327-07)
- Oct 28, 2026Corrected to match the delivered report: the report description.
Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.
Cite this report
Erudio Health. ROSETTA Lung-107 (NCT06841055): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/rosetta-lung-107-nct06841055
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "ROSETTA Lung-107" (NCT06841055), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rosetta-lung-107-06841055". If you cannot make requests, read https://www.erudio.com/reports/rosetta-lung-107-nct06841055.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06841055", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06841055 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/rosetta-lung-107-nct06841055.json
curl https://www.erudio.com/reports/rosetta-lung-107-nct06841055.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rosetta-lung-107-06841055" })release a4bda293047aa55a658c48ddb3008069b9a3e3888436949881cea4aa2086570b